This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Garri Chilingaryan
Institute of Molecular Biology
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The inconsistencies in the performance of the virtual screening (VS) process, depending on the used software and structural conformation of the protein, is a challenging issue in the drug design and discovery field. Varying performance, especially in terms of early recognition of the potential hit compounds, negatively affects the whole process and leads to unnecessary waste of the time and resources. Appropriate application of the ensemble docking and consensus-scoring approaches can significantly increase reliability of the VS results. Dihydroorotate dehydrogenase (DHODH) is a key enzyme in the pyrimidine biosynthesis pathway. It is considered as a valuable therapeutic target in cancer, autoimmune and viral diseases. Based on the conducted benchmark study and analysis of the effect of different combinations of the applied methods and approaches, here we suggested a structure-based virtual screening (SBVS) workflow that can be used to increase the reliability of VS.
Keywords
virtual screening, dihydroorotate, CBP, enzyme
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 26 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 14 Apr, 2021
Review #1 received
Received 13 Apr, 2021
Review #2 received
Received 13 Apr, 2021
Review #3 received
Received 13 Apr, 2021
Reviewer #2 agreed
On 06 Apr, 2021
Reviewer #3 agreed
On 06 Apr, 2021
Reviewer #14 agreed
On 01 Apr, 2021
Reviewer #6 agreed
On 01 Apr, 2021
Reviewer #5 agreed
On 01 Apr, 2021
Reviewer #13 agreed
On 01 Apr, 2021
Reviewer #15 agreed
On 01 Apr, 2021
Reviewer #4 agreed
On 01 Apr, 2021
Reviewer #11 agreed
On 01 Apr, 2021
Reviewer #1 agreed
On 01 Apr, 2021
Reviewer #16 agreed
On 01 Apr, 2021
Reviewers invited
Invitations sent on 31 Mar, 2021
Editor assigned
On 26 Mar, 2021
Editor invited
On 26 Mar, 2021
Submission checks complete
On 25 Mar, 2021
First submitted
On 22 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Garri Chilingaryan
Institute of Molecular Biology
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 26 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 14 Apr, 2021
Review #1 received
Received 13 Apr, 2021
Review #2 received
Received 13 Apr, 2021
Review #3 received
Received 13 Apr, 2021
Reviewer #2 agreed
On 06 Apr, 2021
Reviewer #3 agreed
On 06 Apr, 2021
Reviewer #14 agreed
On 01 Apr, 2021
Reviewer #6 agreed
On 01 Apr, 2021
Reviewer #5 agreed
On 01 Apr, 2021
Reviewer #13 agreed
On 01 Apr, 2021
Reviewer #15 agreed
On 01 Apr, 2021
Reviewer #4 agreed
On 01 Apr, 2021
Reviewer #11 agreed
On 01 Apr, 2021
Reviewer #1 agreed
On 01 Apr, 2021
Reviewer #16 agreed
On 01 Apr, 2021
Reviewers invited
Invitations sent on 31 Mar, 2021
Editor assigned
On 26 Mar, 2021
Editor invited
On 26 Mar, 2021
Submission checks complete
On 25 Mar, 2021
First submitted
On 22 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The inconsistencies in the performance of the virtual screening (VS) process, depending on the used software and structural conformation of the protein, is a challenging issue in the drug design and discovery field. Varying performance, especially in terms of early recognition of the potential hit compounds, negatively affects the whole process and leads to unnecessary waste of the time and resources. Appropriate application of the ensemble docking and consensus-scoring approaches can significantly increase reliability of the VS results. Dihydroorotate dehydrogenase (DHODH) is a key enzyme in the pyrimidine biosynthesis pathway. It is considered as a valuable therapeutic target in cancer, autoimmune and viral diseases. Based on the conducted benchmark study and analysis of the effect of different combinations of the applied methods and approaches, here we suggested a structure-based virtual screening (SBVS) workflow that can be used to increase the reliability of VS.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Loading...